Scholarlink

Background <p>Infants with Kawasaki Disease (KD) have a higher risk of incomplete presentations, IVIG resistance, and coronary artery lesions (CALs). IL-1 plays a key role in the pathogenesis, highlighting its potential as a therapeutic target.</p> Objective <p>To report a multicenter Italian experience and review the literature on anakinra use in KD infants with CALs.</p> Methods <p>We retrospectively reviewed charts of patients aged ≤ 6&#xa0;months treated with anakinra at four Italian centers between 2015 and 2024.</p> <p>A systematic Literature search was also conducted in PubMed, Scopus, Embase, and the Cochrane Library up to October 2024.</p> Results <p>Eight infants were included. The median age at diagnosis was 2.75&#xa0;months. Six had incomplete KD. All were resistant to first-line treatment and all developed CALs, which were detected at a median of 9.5&#xa0;days from fever onset. Anakinra was initiated at a median of 18&#xa0;days from fever onset and 1.5&#xa0;days after CALs detection. One patient received only subcutaneous anakinra. Seven infants underwent intravenous administration (median dose 8.5&#xa0;mg/kg/day), four of whom received an initial bolus (median dose 2.75&#xa0;mg/kg), and six were subsequently switched to subcutaneous dosing. Median total treatment duration was 22.5&#xa0;days. CALs completely resolved in five patients, and improved in two. One treatment-related adverse event was reported.</p> <p>The literature review identified nine additional infants ≤ 6&#xa0;months; seven showed systemic improvement and five had coronary improvement, and no adverse events were reported after anakinra treatment.</p> Conclusion <p>Anakinra may be a promising and well-tolerated option for infants with KD and CALs, especially in IVIG-resistant or high-risk cases. While adverse events were unusual, further studies are needed to confirm its safety and efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月3日

查看全文
  • Giulia Inguscio,
  • Stefano Romano,
  • Marianna Fabi,
  • Livia Gargiullo,
  • Alessandra Marchesi,
  • Maria Cristina Maggio,
  • Maria Vincenza Mastrolia,
  • Giovanni Battista Calabri,
  • Gabriele Simonini,
  • Teresa Giani

摘要

Background

Infants with Kawasaki Disease (KD) have a higher risk of incomplete presentations, IVIG resistance, and coronary artery lesions (CALs). IL-1 plays a key role in the pathogenesis, highlighting its potential as a therapeutic target.

Objective

To report a multicenter Italian experience and review the literature on anakinra use in KD infants with CALs.

Methods

We retrospectively reviewed charts of patients aged ≤ 6 months treated with anakinra at four Italian centers between 2015 and 2024.

A systematic Literature search was also conducted in PubMed, Scopus, Embase, and the Cochrane Library up to October 2024.

Results

Eight infants were included. The median age at diagnosis was 2.75 months. Six had incomplete KD. All were resistant to first-line treatment and all developed CALs, which were detected at a median of 9.5 days from fever onset. Anakinra was initiated at a median of 18 days from fever onset and 1.5 days after CALs detection. One patient received only subcutaneous anakinra. Seven infants underwent intravenous administration (median dose 8.5 mg/kg/day), four of whom received an initial bolus (median dose 2.75 mg/kg), and six were subsequently switched to subcutaneous dosing. Median total treatment duration was 22.5 days. CALs completely resolved in five patients, and improved in two. One treatment-related adverse event was reported.

The literature review identified nine additional infants ≤ 6 months; seven showed systemic improvement and five had coronary improvement, and no adverse events were reported after anakinra treatment.

Conclusion

Anakinra may be a promising and well-tolerated option for infants with KD and CALs, especially in IVIG-resistant or high-risk cases. While adverse events were unusual, further studies are needed to confirm its safety and efficacy.